Comparative Study on the Efficacy and Safety of Amlodipine Besylate Folic Acid Tablets and Enalapril Maleate Folic Acid Tablets in the Treatment of H-Type Hypertension Patients
返回论文页
|更新时间:2022-10-08
|
Comparative Study on the Efficacy and Safety of Amlodipine Besylate Folic Acid Tablets and Enalapril Maleate Folic Acid Tablets in the Treatment of H-Type Hypertension Patients
LI Long, HUANG Jingyuan, WU Jinbin, et al. Comparative Study on the Efficacy and Safety of Amlodipine Besylate Folic Acid Tablets and Enalapril Maleate Folic Acid Tablets in the Treatment of H-Type Hypertension Patients. [J]. 21(9):1036-1038(2021)
DOI:
LI Long, HUANG Jingyuan, WU Jinbin, et al. Comparative Study on the Efficacy and Safety of Amlodipine Besylate Folic Acid Tablets and Enalapril Maleate Folic Acid Tablets in the Treatment of H-Type Hypertension Patients. [J]. 21(9):1036-1038(2021) DOI: 10.14009/j.issn.1672-2124.2021.09.004.
Comparative Study on the Efficacy and Safety of Amlodipine Besylate Folic Acid Tablets and Enalapril Maleate Folic Acid Tablets in the Treatment of H-Type Hypertension Patients
OBJECTIVE: To compare the efficacy and safety of Amlodipine besylate folic acid tablets and Enalapril maleate folic acid tablets in the treatment of H-type hypertension patients. METHODS: A total of 160 Guangxi Zhuang patients diagnosed with H-type hypertension for the first time in Wuming Hospital
Guangxi Medical University from Jan. 2019 to Jan. 2020 were extracted to be divided into the observation group and the control group via the random number table
with 80 cases in each group. The observation group was treated with Amlodipine besylate folic acid tablets
while the control group received Enalapril maleate folic acid tablets
both groups were treated for 6 months.Clinical efficacy
blood pressure [systolic pressure( SBP) and diastolic pressure( DBP) ]
homocysteine( Hcy)level
adverse drug reactions and cardiovascular and cerebrovascular adverse events before and after treatment in two groups were observed. RESULTS: The total effective rate of the observation group and the control group was respectively 88. 75%( 71/80) and 83. 75%( 67/80)
the total effective rate of the observation group was higher than that in the control group
the difference was not statistically significant( P>0. 05). Compared with before treatment
the levels of SBP
DBP and Hcy in two groups decreased significantly after treatment
and the decrease of SBP
DBP and Hcy in the observation group was greater than that in the control group
the differences were statistically significant( P<0. 05). Within 6 months of treatment
the incidence of cardiovascular and cerebrovascular adverse events was 3. 75%( 3/80) in the observation group and 10. 00%( 8/80) in the control group
with no statistically significant difference( P > 0. 05). The incidence of adverse drug reactions was 6. 25%( 5/80) in the observation group
significantly lower than 16. 25%( 13/80) in the control group
the difference was statistically significant( P<0. 05).CONCLUSIONS: Amlodipine benzoate folic acid tablets for H-type hypertension patients shows better results in lowering blood pressure and Hcy levels and lower incidence of adverse drug reactions.